<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677391</url>
  </required_header>
  <id_info>
    <org_study_id>MLAY-02-001</org_study_id>
    <nct_id>NCT00677391</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population</brief_title>
  <official_title>Randomized Trial of Obese Non-Diabetic Malaysians Using Sibutramine: A Randomized Double-Blind Placebo-Controlled Study of Sibutramine in the Management of Obese Subjects in Malaysia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the efficacy and the safety of&#xD;
      sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight&#xD;
      and obese Malaysian subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bodyweight from baseline to final evaluation</measure>
    <time_frame>Wk 0, then, bi-weekly through duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of change in body weight from baseline to final evaluation.</measure>
    <time_frame>Wk 0 and Wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fat mass, total body lean mass, percent of total body lean mass measurements (BodystatÂ® 1500)</measure>
    <time_frame>Wks 0, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Abdominal Fat Mass, Total Abdominal Lean Mass, Percent of Total Abdominal Fat Mass and Percent of Total Abdominal Lean Mass (DEXA Scan)</measure>
    <time_frame>Wk 0 and Wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic measurements (Cholesterol, Triglycerides &amp; Insulin resistance) and SF 36 Quality of life measurement</measure>
    <time_frame>Wk 0, 12 and Wk 24. In addition to the stated time frames, a Quality of life survey was conducted 30 days post study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sibutramine</intervention_name>
    <description>Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-991</other_name>
    <other_name>Meridia</other_name>
    <other_name>Reductil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject did not adequately respond (i.e., did not achieve or maintain &gt; 5%weight&#xD;
             loss) to an appropriate non-pharmacologic weight-reducing regimen (i.e., diet and&#xD;
             exercise) within 3 months prior to Screening.&#xD;
&#xD;
          -  The subject was male or female and between 18 and 65 years of age.&#xD;
&#xD;
          -  The subject has nutritional obesity and BMI &gt;= 27 kg/m2 associated with dyslipidemia&#xD;
             or has BMI &gt;= 30 kg/m2.&#xD;
&#xD;
          -  Dyslipidemia was defined as having at least one of the following three conditions:&#xD;
&#xD;
               -  Low-density lipoprotein (LDL)-cholesterol level of &gt; 3.4 mmol/L (&gt; 130 mg/dL)&#xD;
&#xD;
               -  total cholesterol level of &gt; 5.2 mmol/L (&gt; 200 mg/dL)&#xD;
&#xD;
               -  triglyceride level of &gt; 1.7 mmol/L (&gt; 150 mg/dL). 254&#xD;
&#xD;
          -  If the subject was female&#xD;
&#xD;
               -  she must either not of childbearing potential: defined as postmenopausal for at&#xD;
                  least 2 years or surgically sterile (bilateral tubal ligation, bilateral&#xD;
                  oophorectomy or hysterectomy),&#xD;
&#xD;
               -  or was of childbearing potential and practicing one of the following methods of&#xD;
                  birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device&#xD;
                  (IUD)on contraceptives (oral or parenteral) for the 3-month period prior to Week&#xD;
                  0, a vasectomized partner, total abstinence from sexual intercourse&#xD;
&#xD;
          -  If the subject was female, the results of a urine pregnancy test performed at&#xD;
             Screening and Week 0 were negative.&#xD;
&#xD;
          -  If the subject was female, the subject was not breast-feeding.&#xD;
&#xD;
          -  The subject was judged to be in general good health based upon the results of medical&#xD;
             history, complete physical examination and clinical laboratory tests.&#xD;
&#xD;
          -  The subject was not taking any over-the-counter or prescription drugs, or herbal&#xD;
             products for weight loss during the 4 week period prior to Screening.&#xD;
&#xD;
          -  The subject has voluntarily signed and dated an informed consent form, approved by an&#xD;
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to&#xD;
             undertaking any study-specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence according to the 1997 American Diabetic Association&#xD;
             (ADA)26criteria of type 1 or type 2 diabetes mellitus, i.e., fasting plasma glucose&#xD;
             level &gt;= 7.0 mmol/L.&#xD;
&#xD;
          -  Inadequately controlled hypertension having systolic blood pressure &gt;= 145 mmHg or&#xD;
             diastolic blood pressure &gt;= 90 mmHg (average of three measurements) or any&#xD;
             hypertensive subjects taking &gt; 3 medications to control blood pressure.&#xD;
&#xD;
          -  History of Gilles de la Tourette's Syndrome.&#xD;
&#xD;
          -  Use within 4 weeks prior to Week 0 of any of the following:&#xD;
&#xD;
               -  Monoamine oxidase inhibitors (MAOIs): used to treat depression and Parkinson's&#xD;
                  disease.&#xD;
&#xD;
               -  Medications that regulate the neurotransmitter serotonin in the brain (SSRIs):&#xD;
                  used to treat psychiatric disorders and to stop smoking.&#xD;
&#xD;
               -  Amino acids: used to treat sleep disorders.&#xD;
&#xD;
               -  Certain antimigraine drugs (such as sumatriptan, dihydroergotamine).&#xD;
&#xD;
               -  Opioids (such as pentazocine, pethidine, fentanyl, dextromethorphan).&#xD;
&#xD;
          -  Organic causes of obesity (e.g., hypothyroidism).&#xD;
&#xD;
          -  History of major eating disorders, such as anorexia nervosa or bulimia nervosa.&#xD;
&#xD;
          -  History of benign prostatic hyperplasia with urinary retention.&#xD;
&#xD;
          -  History of neurological disorders such as seizures.&#xD;
&#xD;
          -  History of documented psychiatric illnesses such as anxiety, depression, bipolar&#xD;
             disorder or schizophrenia or having psychotic symptoms.&#xD;
&#xD;
          -  History or evidence of severe renal or hepatic impairments.&#xD;
&#xD;
          -  History of narrow-angle glaucoma.&#xD;
&#xD;
          -  History of coronary artery disease, congestive heart failure, peripheral arterial&#xD;
             occlusive disease, arrhythmia or cerebrovascular disease (transient ischemic attacks&#xD;
             or strokes).13. History or evidence of hyperthyroidism.&#xD;
&#xD;
          -  Persistent tachycardia at rest, i.e., heart rate &gt;100 bpm (average of 3 measurements).&#xD;
&#xD;
          -  History of primary or secondary pulmonary hypertension.&#xD;
&#xD;
          -  Underlying or suspected phaeochromocytoma.&#xD;
&#xD;
          -  Known hypersensitivity to sibutramine hydrochloride monohydrate or any other component&#xD;
             of the product.&#xD;
&#xD;
          -  Known history of drug or alcohol abuse.&#xD;
&#xD;
          -  Has previous history with the use of sibutramine.&#xD;
&#xD;
          -  Any other medical illnesses judged by the investigator that may compromise the&#xD;
             efficacy or safety of sibutramine.&#xD;
&#xD;
          -  Unlikely to cooperate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>May 13, 2008</last_update_submitted>
  <last_update_submitted_qc>May 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Peter Bacher, Global Project Head</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

